Agomelatine facilitates positive versus negative affective processing in healthy volunteer models

Catherine J. Harmer, C de Bodinat, Gerry Dawson, Colin Dourish, Lara Waldenmaier , Sally Adams, Philip Cowen , Guy Goodwin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Agomelatine is a new antidepressant with a novel profile of pharmacological action. The clinical efficacy of agomelatine has been established in major depression, but its actions on emotional bias are unknown. Consequently, the current experimental study assessed the effect of agomelatine on emotional processing in healthy volunteers using an Emotional Test Battery shown to be sensitive to serotonin and noradrenaline reuptake inhibitors. Volunteers were randomized to receive placebo, 25 mg or 50 mg of agomelatine over a 7-day period in a double-blind parallel groups design. Emotional processing (n = 48) was assessed on the morning of day 8 using the Emotional Test Battery which included facial expression recognition, emotional memory, attentional visual probe and emotion-potentiated startle. Mood and subjective state were monitored before and during treatment. Agomelatine (25 mg) decreased subjective ratings of sadness, reduced recognition of sad facial expressions, improved positive affective memory and reduced the emotion-potentiated startle response. The results show that agomelatine has more selective effects on the processing of social facial cues than conventional antidepressants, which could contribute to less blunting of emotional experience. The study highlights the potential value of volunteer models in drug development for screening and profiling of novel antidepressants.
Original languageEnglish
Pages (from-to)1159-1167
Number of pages9
JournalJournal of Psychopharmacology
Volume25
Early online date21 Jul 2010
DOIs
Publication statusPublished - 1 Sep 2011

Cite this

Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. / Harmer, Catherine J.; de Bodinat, C; Dawson, Gerry ; Dourish, Colin ; Waldenmaier , Lara ; Adams, Sally; Cowen , Philip ; Goodwin, Guy .

In: Journal of Psychopharmacology , Vol. 25, 01.09.2011, p. 1159-1167.

Research output: Contribution to journalArticle

Harmer, CJ, de Bodinat, C, Dawson, G, Dourish, C, Waldenmaier , L, Adams, S, Cowen , P & Goodwin, G 2011, 'Agomelatine facilitates positive versus negative affective processing in healthy volunteer models', Journal of Psychopharmacology , vol. 25, pp. 1159-1167. https://doi.org/10.1177/0269881110376689
Harmer, Catherine J. ; de Bodinat, C ; Dawson, Gerry ; Dourish, Colin ; Waldenmaier , Lara ; Adams, Sally ; Cowen , Philip ; Goodwin, Guy . / Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. In: Journal of Psychopharmacology . 2011 ; Vol. 25. pp. 1159-1167.
@article{3eb95ffe581849458343317228513921,
title = "Agomelatine facilitates positive versus negative affective processing in healthy volunteer models",
abstract = "Agomelatine is a new antidepressant with a novel profile of pharmacological action. The clinical efficacy of agomelatine has been established in major depression, but its actions on emotional bias are unknown. Consequently, the current experimental study assessed the effect of agomelatine on emotional processing in healthy volunteers using an Emotional Test Battery shown to be sensitive to serotonin and noradrenaline reuptake inhibitors. Volunteers were randomized to receive placebo, 25 mg or 50 mg of agomelatine over a 7-day period in a double-blind parallel groups design. Emotional processing (n = 48) was assessed on the morning of day 8 using the Emotional Test Battery which included facial expression recognition, emotional memory, attentional visual probe and emotion-potentiated startle. Mood and subjective state were monitored before and during treatment. Agomelatine (25 mg) decreased subjective ratings of sadness, reduced recognition of sad facial expressions, improved positive affective memory and reduced the emotion-potentiated startle response. The results show that agomelatine has more selective effects on the processing of social facial cues than conventional antidepressants, which could contribute to less blunting of emotional experience. The study highlights the potential value of volunteer models in drug development for screening and profiling of novel antidepressants.",
author = "Harmer, {Catherine J.} and {de Bodinat}, C and Gerry Dawson and Colin Dourish and Lara Waldenmaier and Sally Adams and Philip Cowen and Guy Goodwin",
year = "2011",
month = "9",
day = "1",
doi = "10.1177/0269881110376689",
language = "English",
volume = "25",
pages = "1159--1167",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "Sage Publications",

}

TY - JOUR

T1 - Agomelatine facilitates positive versus negative affective processing in healthy volunteer models

AU - Harmer, Catherine J.

AU - de Bodinat, C

AU - Dawson, Gerry

AU - Dourish, Colin

AU - Waldenmaier , Lara

AU - Adams, Sally

AU - Cowen , Philip

AU - Goodwin, Guy

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Agomelatine is a new antidepressant with a novel profile of pharmacological action. The clinical efficacy of agomelatine has been established in major depression, but its actions on emotional bias are unknown. Consequently, the current experimental study assessed the effect of agomelatine on emotional processing in healthy volunteers using an Emotional Test Battery shown to be sensitive to serotonin and noradrenaline reuptake inhibitors. Volunteers were randomized to receive placebo, 25 mg or 50 mg of agomelatine over a 7-day period in a double-blind parallel groups design. Emotional processing (n = 48) was assessed on the morning of day 8 using the Emotional Test Battery which included facial expression recognition, emotional memory, attentional visual probe and emotion-potentiated startle. Mood and subjective state were monitored before and during treatment. Agomelatine (25 mg) decreased subjective ratings of sadness, reduced recognition of sad facial expressions, improved positive affective memory and reduced the emotion-potentiated startle response. The results show that agomelatine has more selective effects on the processing of social facial cues than conventional antidepressants, which could contribute to less blunting of emotional experience. The study highlights the potential value of volunteer models in drug development for screening and profiling of novel antidepressants.

AB - Agomelatine is a new antidepressant with a novel profile of pharmacological action. The clinical efficacy of agomelatine has been established in major depression, but its actions on emotional bias are unknown. Consequently, the current experimental study assessed the effect of agomelatine on emotional processing in healthy volunteers using an Emotional Test Battery shown to be sensitive to serotonin and noradrenaline reuptake inhibitors. Volunteers were randomized to receive placebo, 25 mg or 50 mg of agomelatine over a 7-day period in a double-blind parallel groups design. Emotional processing (n = 48) was assessed on the morning of day 8 using the Emotional Test Battery which included facial expression recognition, emotional memory, attentional visual probe and emotion-potentiated startle. Mood and subjective state were monitored before and during treatment. Agomelatine (25 mg) decreased subjective ratings of sadness, reduced recognition of sad facial expressions, improved positive affective memory and reduced the emotion-potentiated startle response. The results show that agomelatine has more selective effects on the processing of social facial cues than conventional antidepressants, which could contribute to less blunting of emotional experience. The study highlights the potential value of volunteer models in drug development for screening and profiling of novel antidepressants.

U2 - 10.1177/0269881110376689

DO - 10.1177/0269881110376689

M3 - Article

VL - 25

SP - 1159

EP - 1167

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

ER -